Peptide Nanofiber Therapy Crosses Blood-Brain Barrier and Reduces Stroke Damage in Mice | Research

The takeaway

Systemically administered IKVAV peptide amphiphile assemblies crossed the blood-brain barrier, localized to the ischemic hemisphere, and significantly reduced stroke infarct size in mice.

IV to brain
Peptide nanofibers crossed the blood-brain barrier after simple IV injection and concentrated in the stroke-damaged area

What the researchers found

Systemically delivered IKVAV-PA crossed the BBB, localized to the ischemic hemisphere (confirmed by intravital imaging), and significantly reduced infarct volume vs saline at 7 days post-stroke with good organ biocompatibility.

Why it matters

Stroke is a leading cause of disability. An injectable peptide therapy that protects the brain after reperfusion could save millions of neurons and improve functional outcomes.

How the study worked

Transient MCAO in CX3CR1-GFP mice, IV IKVAV-PA administration at reperfusion, intracranial intravital and wide-field imaging for PA distribution, cresyl violet staining for infarct volume at 7 days, and systemic organ histology.

What this study cannot tell us

Mouse model. Single timepoint (7 days). Functional behavioral outcomes not assessed. PA pharmacokinetics not fully characterized.

How to read the evidence

Preclinical proof-of-concept with imaging confirmation and efficacy. Novel therapeutic approach requiring further development.

When this study was published

Published in 2025.

The bigger picture

Self-assembling peptide amphiphiles that can cross the BBB after systemic injection represent a new paradigm for treating acute brain injuries with precision biomaterials.

Questions still open

Does infarct reduction translate to improved functional recovery?
How long do the peptide assemblies persist in the brain?
Could this be combined with tPA or mechanical thrombectomy in clinical trials?

Common questions

How does a peptide nanofiber treat stroke?

The peptide self-assembles into nanofibers that display the IKVAV sequence, which promotes neuron survival. When injected into the bloodstream, they cross into the brain and concentrate in the stroke-damaged area, reducing brain cell death.

Could this be used alongside standard stroke treatment?

That is the goal. Standard stroke treatment restores blood flow (which can cause secondary damage). This peptide therapy would be given at the same time to protect brain cells during and after blood flow restoration.

Read the original research

Toward development of a dynamic supramolecular peptide therapy for acute ischemic stroke.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, e00820

View on PubMed ↗Publisher’s paper ↗

Citation

Gao, Zijun; Andrade da Silva, Luisa Helena; Li, Zhiwei; Chen, Feng; Smith, Cara; Lipfert, Zoie; Martynowicz, Ryan; Arias, Erika; Muller, William A; Sullivan, David P; Stupp, Samuel I; Batra, Ayush. (2026). Toward development of a dynamic supramolecular peptide therapy for acute ischemic stroke.. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, e00820. https://doi.org/10.1016/j.neurot.2025.e00820